A study funded by the National Institutes of Health has found that adults who were hospitalized for a severe infection, such ...

NIH funded study finds infection-related hospitalizations linked to increased risk of heart failure: Bethesda, Maryland Thursday, February 13, 2025, 18:00 Hrs [IST] A study funded ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples, that can be obtained from a cheek swab or blood test, they can improve identification of people ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

The study is being sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institute of Health (NIH). Fostamatinib, marketed in the U.S. as TAVALISSE ...

New research explores how point-of-care lung ultrasound can improve prehospital identification of acute heart failure ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to assess ...

Co-authors reported relationships with NIH, NHLBI, Bayer, Alpha-1 Foundation, AstraZeneca, Northpond Laboratories, Regeneron, Sanofi, and Apogee. Labaki disclosed no relevant conflicts of interest.

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.